People · Operator
Named in public records as an officer, director or promoter · active 2016–2016 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aradigm Corp | — | Pharmaceuticals | Series B | $27.1M | $782.1M | 2016 |
David D. Bell at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David D. Bell on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Virgil Thompson | 1 | 4 |
| John M. Siebert | 1 | 4 |
| Frank Barker | 1 | 1 |
| John Siebert | 1 | 1 |
| Igor Gonda | 1 | 1 |
| Nancy Pecota | 1 | 1 |
| Virgil D. Thompson | 1 | 1 |
| Frederick D. Hudson | 1 | 1 |
| Nancy E. Pecota | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.